Sugi Predict

Sugi Predict / Compounds / SCHEMBL2336414

SCHEMBL2336414

SCHEMBL2336414

Cc1ccc(C(=O)O)c(CC(=O)O)c1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 1/20 0.54
▸ MAPT P10636 3/20 0.50
▸ ALOX15 P16050 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ CSNK2A1 P68400 1/20 0.50
▸ PTGS2 P35354 5/20 0.48
▸ APEX1 P27695 1/20 0.44
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ ABCB11 O95342 1/20 0.43
▸ PTGS1 P23219 1/20 0.43
▸ PPARG P37231 1/20 0.43
▸ NR1I3 Q14994 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ GAA P10253 1/20 0.42
▸ HTT P42858 1/20 0.41
▸ KDM4C Q9H3R0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1821912 0.85 SRC (0.59) SRCMAPTALOX15SMN1; SMN2CSNK2A1
SCHEMBL1549076 0.84 CSNK2A1 (0.53) SMN1; SMN2CSNK2A1MEN1KMT2AALDH1A1
SCHEMBL623349 0.82 CSNK2A1 (0.52) SRCSMN1; SMN2CSNK2A1MEN1KMT2A
SCHEMBL12258207 0.82 SRC (0.65) SRCMAPTALOX15SMN1; SMN2PTGS2
SCHEMBL20434221 0.81 NPSR1 (0.53) MAPTCSNK2A1MEN1KMT2AALDH1A1
SCHEMBL7774557 0.81 CSNK2A1 (0.50) CSNK2A1MEN1KMT2AALDH1A1KDM4E
SCHEMBL30388279 0.81 CSNK2A1 (0.50) SRCSMN1; SMN2CSNK2A1MEN1KMT2A
SCHEMBL15462885 0.81 CSNK2A1 (0.50) SRCSMN1; SMN2CSNK2A1MEN1KMT2A
SCHEMBL20943211 0.81 CSNK2A1 (0.50) SMN1; SMN2CSNK2A1MEN1KMT2AALDH1A1
SCHEMBL18280409 0.81 CSNK2A1 (0.50) SMN1; SMN2CSNK2A1MEN1KMT2APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025042797-A1 TRIM7 INHIBITORS AND USES THEREOF SHATTUCK LABS, INC. (US) 2025-02-27 — — WO disclosed
EP-2059565-B1 MODIFIED COLORANTS WITH ALIPHATIC POLY-ACID GROUPS CABOT CORP (US) 2014-06-11 — — EP disclosed
US-8021471-B2 Modified colorants with aliphatic poly-acid groups CABOT CORPORATION (US) 2011-09-20 — — US disclosed
US-8021471-B2 Modified colorants with aliphatic poly-acid groups CABOT CORPORATION (US) 2011-09-20 — — US disclosed
US-20110224208-A1 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2011-09-15 — — US disclosed
EP-2358682-A2 ISOQUINOLONE DERIVATIVES AS INHIBITORS OF PLAVIVIRUS REPLICATION Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2011-08-24 — — EP disclosed
WO-2010055164-A2 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2010-05-20 — — WO disclosed
US-7393625-B2 Photothermographic material FUJIFILM CORPORATION (JP) 2008-07-01 — — US disclosed
US-7393625-B2 Photothermographic material FUJIFILM CORPORATION (JP) 2008-07-01 — — US disclosed
US-20080083347-A1 Readily dispersible in liquid vehicles; stability; ink jet pigments; quality optical density on plain paper CABOT CORPORATION 2008-04-10 — — US disclosed
US-20080083347-A1 Readily dispersible in liquid vehicles; stability; ink jet pigments; quality optical density on plain paper CABOT CORPORATION 2008-04-10 — — US disclosed
WO-2008027405-A2 MODIFIED COLORANTS WITH ALIPHATIC POLY-ACID GROUPS CABOT CORPORATION (US) 2008-03-06 — — WO disclosed
EP-1840646-A1 Photothermographic material FUJIFILM Corporation (JP) 2007-10-03 — — EP disclosed
US-20070224555-A1 Photothermographic material FUJIFILM CORPORATION 2007-09-27 — — US disclosed
US-20070224555-A1 Photothermographic material FUJIFILM CORPORATION 2007-09-27 — — US disclosed
EP-0590455-B1 Antiarrhythmic and cardioprotective substituted 1(2H)-isoquinolines, process for their production, medicament containing them and their use for the production of a medicament for combating heart failures HOECHST AG (DE) 2000-12-27 — — EP disclosed
US-5416094-A Antiarrhythmic and cardioprotective substituted -1(2H)isoquinolines, medicament containing them, and their use for combating heart failures HOECHST AKTIENGESELLSCHAFT (DE) 1995-05-16 — — US disclosed
US-5330991-A Tetrahydroisoquinoline compounds and fungicides containing the same TOSOH CORPORATION (JP) 1994-07-19 — — US disclosed
EP-0590455-A1 Antiarrhythmic and cardioprotective substituted -1(2H)Isoquinolines, process for their production, medicament containing them and their use for the production of a medicament for combating heart failures HOECHST AKTIENGESELLSCHAFT (DE) 1994-04-06 — — EP disclosed
EP-0528553-A1 Tetrahydroisoquinoline derivatives, processes for producing the same and fungicides containing the same TOSOH CORPORATION (JP) 1993-02-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224208-A1 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION MAVS, IRF3, EIF2AK2 SRC 2913/4885MAPT 3706/4885ALOX15 2141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.